title: Preparation of anti-tumor nanoparticle and its inhibition to peritoneal dissemination of colon cancer.
abstract: BACKGROUND
  5-Fluorouracil (5-FU) is one of the most classic chemotherapy drugs. Nanoparticle drug delivery vehicles offer superiority over target effect enhancement and abatement of side effects. Little is known however as to the specific effect of nanoparticle on peritoneal dissemination of colon cancer. The aim of this study is to prepare one NPs (nanoparticles) loaded with 5-FU and investigate the characteristic of NPs and the role of it in peritoneal metastasis nodules formation of human colon cancer.
  
  
  RESULTS
  Prepared the NPs (nanoparticles) loaded with 5-FU (5-Fluorouracil) by PEG-PLGA with the method of double emulsion. Then evaluate the characteristics of the NPs by scanning electron microscopy, analyzing the particle diameter distribution and determining the loading efficiency. Detect the release features of NPs in vitro and in vivo. Nude mice with peritoneal metastases were treated with 5-FU solution or 5-FU-NPs through peritoneal cavity. Count the nodules on peritoneum and mesenterium and survey the size of them. We got NPs with average-diameter of 310 nm. In vitro release test shows NPs can release equably for 5 days with release rate of 99.2%. In vivo, NPs group can keep higher plasma concentration of 5-FU longer than it in solution group. The number of peritoneal dissemination nodule below 1 mm in 5-FU-sol group(17.3 ± 3.5) and 5-FU-NP group(15.2 ± 3.2) is less than control group(27.2 ± 4.7)(P<0.05). The total number of nodules in 5-FU-NP group(28.7 ± 4.2) is significantly smaller than in 5-FU-sol group(37.7 ± 6.3) (P<0.05).
  
  
  CONCLUSIONS
  The novel anti-tumor nanoparticles loaded with 5-FU by PEG-PLGA can release maintain 5 days and have inhibitory action to peritoneal dissemination of colon cancer in mice.
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Qingchao
authors.initials: Q
authors.lastname: Tang
authors.affiliation: Department of Colorectal Surgery, The Third Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Yihui
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Huang
authors.affiliation: Department of Colorectal Surgery, The Third Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: You
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Guiyu
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Yinggang
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Jiang
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Yu
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Muhammad
authors.affiliation: Department of Colorectal Cancer Surgery, Cancer Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
authors.forename: Xishan
authors.initials: X
authors.lastname: Wang
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016503:Drug Delivery Systems; D005472:Fluorouracil / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil